Ligand Pharmaceuticals (LGND) Accounts Payables (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Accounts Payables data on file, last reported at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 1.9% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 1.9% YoY), and the FY2025 full-year result was $3.2 million, down 38.12% from the prior year.
• Accounts Payables rose to $5.3 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $19.2 million in Q2 2022 to a low of $1.8 million in Q2 2024.
• A 5-year average of $6.3 million and a median of $5.3 million in 2026 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 84.42% in 2023 and surged 378.75% in 2025, its largest moves.
• Tracing LGND's Accounts Payables over 5 years: stood at $5.3 million in 2022, then sank by 54.27% to $2.4 million in 2023, then jumped by 115.62% to $5.2 million in 2024, then sank by 38.12% to $3.2 million in 2025, then surged by 62.57% to $5.3 million in 2026.
• Business Quant data shows LGND's Accounts Payables at $5.3 million in Q1 2026, $3.2 million in Q4 2025, and $3.7 million in Q3 2025.